SAN FRANCISCO -- Crinecerfont (Crenessity) may help improve metabolic profiles of adults and children with classic congenital adrenal hyperplasia (CAH), analyses of phase III CAHtalyst trial data ...
SAN DIEGO, July 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of new one-year data from the CAHtalyst™ Adult study of CRENESSITY® (crinecerfont) ...
In adults, open-label data showed a sustained steroid-reducing benefit with the oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist, according to findings presented by Sonal Vaid, MD ...
PITTSBURGH, Dec. 23, 2024 /PRNewswire/ -- PANTHERx ® Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce that it was selected by ...
CRENESSITY, a First-in-Class Treatment for Classic Congenital Adrenal Hyperplasia (CAH), is now commercially available in the U.S. CAH-trained pharmacists are available 24/7 to support patients with ...
The US Food and Drug Administration has approved crinecerfont (Crenessity) for use in combination with glucocorticoids in the treatment of adults and children aged 4 years or older with classic ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved crinecerfont to treat patients with congenital adrenal hyperplasia. The drug directly reduces ...
Crenessity is expected to be available commercially in approximately 1 week through PANTHERx Rare, a specialty pharmacy. The Food and Drug Administration (FDA) has approved Crenessity TM (crinecerfont ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback